CytomX Therapeutics (NASDAQ: CTMX) insider transactions
In the twelve months to 10 November 2026, executives and directors of CytomX Therapeutics reported 5 open-market sales of 192,687 shares ($1.2m) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 3 August 2026 | Carvajal Alejandra | Chief Legal Officer | Grant or award | +100,000 | — | 100,000 | Form 4 |
| 15 June 2026 | Ogden Christopher | Chief Financial Officer | Open-market sale | −1,624 | $3.05 | 295,324 | Form 4 |
| 17 March 2026 | Ogden Christopher | Chief Financial Officer | Open-market sale | −19,323 | $6.42 | 296,948 | Form 4 |
| 17 March 2026 | Belvin Marcia | SVP, Chief Scientific Officer | Open-market sale | −31,492 | $6.42 | 300,760 | Form 4 |
| 17 March 2026 | McCarthy Sean A. | CEO | Open-market sale | −118,969 | $6.42 | 1,078,922 | Form 4 |
| 17 March 2026 | Chu Yu-Waye | Chief Medical Officer | Open-market sale | −21,279 | $6.42 | 189,446 | Form 4 |
| 2 February 2026 | McCarthy Sean A. | CEO | Grant or award | +210,000 | — | 1,197,891 | Form 4 |
| 2 February 2026 | Ogden Christopher | Chief Financial Officer | Grant or award | +90,000 | — | 316,271 | Form 4 |
| 2 February 2026 | Belvin Marcia | SVP, Chief Scientific Officer | Grant or award | +60,000 | — | 332,252 | Form 4 |
| 2 February 2026 | Chu Yu-Waye | Chief Medical Officer | Grant or award | +75,000 | — | 210,725 | Form 4 |
| 2 February 2026 | Lester Rachael | Chief Business Officer | Grant or award | +20,000 | — | 20,000 | Form 4 |
| 6 November 2025 | McCarthy Sean A. | CEO | Open-market sale | −101,793 | $4.54 | 987,891 | Form 4 |
| 16 June 2025 | McCarthy Sean A. | CEO | Open-market sale | −55,511 | $2.69 | 1,089,684 | Form 4 |
| 16 June 2025 | Belvin Marcia | SVP, Chief Scientific Officer | Open-market sale | −13,884 | $2.69 | 272,252 | Form 4 |
| 16 June 2025 | Ogden Christopher | Chief Financial Officer | Open-market sale | −10,614 | $2.69 | 226,271 | Form 4 |
| 13 June 2025 | McCarthy Sean A. | CEO | Option exercise | +150,000 | — | 1,145,195 | Form 4 |
| 13 June 2025 | Belvin Marcia | SVP, Chief Scientific Officer | Option exercise | +37,500 | — | 286,136 | Form 4 |
| 13 June 2025 | Ogden Christopher | Chief Financial Officer | Open-market sale | −1,641 | $2.95 | 199,385 | Form 4 |
| 13 June 2025 | Ogden Christopher | Chief Financial Officer | Option exercise | +37,500 | — | 236,885 | Form 4 |
| 18 March 2025 | Belvin Marcia | SVP, Chief Scientific Officer | Open-market sale | −19,512 | $0.60 | 248,636 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the CytomX Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.